FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

NCT06185569 · clinicaltrials.gov ↗
RECRUITING
Status
4500
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Centre Hospitalier Universitaire de Besancon